Concepedia

Evaluation of the effect of food on the pharmacokinetics of axitinib in healthy volunteers

Yazdi K. Pithavala, Ying Chen, Melvin Toh, Paulina Selaru, Robert R. LaBadie, May Garrett, Brian Hee, Janessa Mount, Grace Ni, Karen J. Klamerus,

Cancer Chemotherapy and Pharmacology · 2012 · 41 citations · 14 references

DOI

Concepts

References

14

Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3

Dana D. Hu‐Lowe, Helen Y. Zou, Maren L. Grazzini et al. · Clinical Cancer Research · 2008 · 628 citations

, , +17

Axitinib Is an Active Treatment for All Histologic Subtypes of Advanced Thyroid Cancer: Results From a Phase II Study

Ezra E.W. Cohen, Lee S. Rosen, Everett E. Vokes et al. · Journal of Clinical Oncology · 2008 · 622 citations · Full text

, , +14

Phase I Trial of the Oral Antiangiogenesis Agent AG-013736 in Patients With Advanced Solid Tumors: Pharmacokinetic and Clinical Results

Hope S. Rugo, Roy S. Herbst, Glenn Liu et al. · Journal of Clinical Oncology · 2005 · 485 citations · Full text

, , +17

Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study

Olivier Rixe, Ronald M. Bukowski, M. Dror Michaelson et al. · The Lancet Oncology · 2007 · 436 citations

, , +14

Phase II Study of Axitinib in Sorafenib-Refractory Metastatic Renal Cell Carcinoma

Brian I. Rini, George Wilding, Gary R. Hudes et al. · Journal of Clinical Oncology · 2009 · 328 citations · Full text

, , +17